11.11.2009 • News

Sanofi to Buy Helvepharm

Drugmaker Sanofi-Aventis has agreed to buy generics maker Helvepharm from Swiss health care group Von Rose, boosting its position in copy-cat generics medicines. Helvepharm expects sales of CHF31 million ($29.03 million) in 2009 and has a Swiss market share of about 5.4 %, Von Rose said, without giving further financial details of the transaction. Sanofi's chief executive, Chris Viehbacher, has said he aims to focus on small and mid-sized deals in generics, emerging markets, vaccines, consumer health and biotechnology.

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.